The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | The efficacy of a novel, triple combination in the treatment of MM
Patients diagnosed with multiple myeloma (MM) are increasingly being treated with a combination of immunomodulatory drugs and proteasome inhibitors, with some triple combinations identified as particularly promising options. Shaji Kumar, MD from the Mayo Clinic, Rochester, MN, USA speaks to us about the results of phase I/II study (NCT01217957) which examined the efficacy of treating newly diagnosed MM patients, who did not undergo stem cell transplant, with a combination of ixazomib and lenalidomide-dexamethasone. This interview was recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
